M K Padmasree, Nelamangala Kiran
Anaesthesiology, Sri Devaraj Urs Medical College, Kolar, IND.
Cureus. 2023 Feb 19;15(2):e35196. doi: 10.7759/cureus.35196. eCollection 2023 Feb.
Tracheal intubation and laryngoscopy may cause sympathetic stimulation, which can cause tachycardia and hypertension. To abolish the pressor response to laryngoscopy and endotracheal intubation, many medication combinations have been tried with varying degrees of efficacy.
This randomized comparative study was double-blinded and included 106 subjects. Patients including those aged 18-60 belong to the American Society of Anesthesiologists (ASA) 1 and 2. These subjects were divided into two study groups. Group A received dexmedetomidine 0.5mcg/kg (200mcg diluted in 50ml syringe with normal saline (NS) up to 50cc 4mcg/ml) through an infusion pump over 40min before induction. Group B received dexmedetomidine intranasally (1mcg/kg) in undiluted which is prepared from parental preparation (100mcg/ml) and an equivalent dose of NS to the other group. The intranasal drug was dripped into both nostrils in equal volume using a 1ml syringe in a supine head-down position about 40min before induction. Both groups received an intravenous placebo and an intranasal placebo with normal saline.
In our study, intranasal and intravenous groups were compared. There was no statistically significant difference in hemodynamic variables like heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) between the two groups (majority p value >0.05). Hence both routes can be preferred for attenuation of pressor responses.
Study findings demonstrate dexmedetomidine can be utilized as a premedication to lessen hemodynamic surges during endotracheal intubation with more or less the same efficacy via intranasal and intravenous routes. This result could be attributable to the fact that both intravenous and intranasal dexmedetomidine stop central catecholamine levels from rising.
气管插管和喉镜检查可能会引起交感神经刺激,进而导致心动过速和高血压。为消除喉镜检查和气管插管引起的升压反应,人们尝试了多种药物组合,疗效各异。
本随机对照研究采用双盲法,纳入了106名受试者。患者年龄在18至60岁之间,属于美国麻醉医师协会(ASA)1级和2级。这些受试者被分为两个研究组。A组在诱导前40分钟通过输液泵给予右美托咪定0.5微克/千克(200微克用生理盐水(NS)稀释至50毫升注射器中,最终浓度为4微克/毫升)。B组在诱导前约40分钟,以仰卧头低位,使用1毫升注射器将未稀释的右美托咪定(1微克/千克)经鼻滴入双侧鼻孔,该未稀释药物由静脉制剂(100微克/毫升)配制而成,且给予与另一组等量体积的NS。两组均接受静脉安慰剂和鼻内生理盐水安慰剂。
在我们的研究中,对经鼻组和静脉组进行了比较。两组之间的心率(HR)、收缩压(SBP)、舒张压(DBP)和平均动脉压(MAP)等血流动力学变量无统计学显著差异(大多数p值>0.05)。因此,两种给药途径均可用于减轻升压反应。
研究结果表明,右美托咪定可作为术前用药,通过经鼻和静脉途径减轻气管插管期间的血流动力学波动,且疗效大致相同。这一结果可能归因于静脉和经鼻给予右美托咪定都能阻止中枢儿茶酚胺水平升高。